Acucela surges after $148m Japan IPO
This article was originally published in Scrip
Executive Summary
The US ophthalmic disease venture Acucela has floated on the Mothers high-tech bourse of the Tokyo Stock Exchange, raising JPY15.15bn (around $148m) to progress its lead drug emixustat and other projects.